Vimarsana
Biggest News Aggregation in the World

Page 13 - Risk Evaluation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Risk Evaluation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Risk Evaluation Today - Breaking & Trending Today

Stein, lawmakers square off again in abortion pill lawsuit filings - Vimarsana News

Stein, lawmakers square off again in abortion pill lawsuit filings

State Attorney General Josh Stein and Republican state legislative leaders offered a federal judge opposing arguments this week in a lawsuit challenging North Carolina’s abortion pill restrictions.

Stein, lawmakers square off again in abortion pill lawsuit filings - Vimarsana News

Stein, lawmakers square off again in abortion pill lawsuit filings

State Attorney General Josh Stein and Republican state legislative leaders offered a federal judge opposing arguments this week in a lawsuit challenging North Carolina’s abortion pill restrictions. US District Judge Catherine Eagles asked parties in the case, Bryant v. Stein, to submit briefs Monday. Eagles will render a decision in the case without holding a trial.

FDA Completes Bioresearch Monitoring Inspection of Pz-Cel for Recessive Dystrophic Epidermolysis Bullosa - Vimarsana News

FDA Completes Bioresearch Monitoring Inspection of Pz-Cel for Recessive Dystrophic Epidermolysis Bullosa

This announcement is part of the overall evaluation period for the treatment, as the PDUFA target action date for pz-cel remains May 2024.

Maine joins multistate lawsuit against FDA over abortion drug - Vimarsana News

Maine joins multistate lawsuit against FDA over abortion drug

Maine and 17 other states are suing the federal agency, accusing it of maintaining restrictions on mifepristone even though it has been safely used to induce abortions for decades.

Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy - Vimarsana News

Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy

Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a manufacturing process change resulting in a shorter manufacturing time for Yescarta® (axicabtagene ciloleucel). With this approval, Kite’s median turnaround time (TAT) in the U.S. is anticipated ...